Table 2

Antitumor activity of mixed Z and cisplatin against SK-OV-3 tumor implanted in nude mice^2-a

Complex	Treatment Schedule^2-b	Dose	Total Dose	%TWI^2-c (after the First Treatment)	%TWI^2-c (after the Second Treatment)	%TWI^2-c (after the Third Treatment)	%TWI^2-c (on Day 31 from Tumor Implant)
		mg/kg/day	mg/kg
Cisplatin	q7d × 3	2	6	18	45	43	40^2-d
		4	12	41	40	48	52^2-e
Mixed Z	q7d × 3	2	6	6	30	22	50^2-e
		4	12	17	49	44	42^2-d

↵2-a Three groups of 10 CD-1 female nude (nu/nu) mice were injected s.c. with a SK-OV-3 cell suspension (2 × 10⁶/cells/mouse) into the right flank. On day 7 after tumor implant, when treatment started, a tumor was evident—although not measurable by caliper—in all mice.
↵2-b Treatment with cisplatin or mixed Z (freshly dissolved in sterile saline) was performed by three i.p. administrations on days 7, 14, and 21 after tumor implant (q7d × 3).
↵2-c %TWI, percentage of tumor weight inhibition of treated mice vs. controls on days 9, 16, 23, and 31 (nadir of cisplatin effect) from tumor implant.
↵2-d Statistical analysis by Mann-Whitney nonparametric test on TWIs calculated 10 days after the last treatment; P < .05;
↵2-e Statistical analysis by Mann-Whitney nonparametric test on TWIs calculated 10 days after the last treatment; P < .01.